Page 1450 - Williams Hematology ( PDFDrive )

1424 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1425

617. Buchner T, Schlenk RF, Schaich M, et al: Acute myeloid leukemia (AML): Different 648. Cullis JO, Duncombe AS, Dudley JM, et al: Acute leukaemia in Jehovah’s Witnesses.
treatment strategies versus a common standard arm—Combined prospective analysis Br J Haematol 100:664, 1998.
by the German AML intergroup. J Clin Oncol 30:3604, 2012. 649. Castagnola C, Nozza A, Corso A, Bernasconi C: The value of combination therapy in
618. Rowe JM, Neuberg D, Friedenberg W, et al: A phase 3 study of three induction regi- adult acute myeloid leukemia with central nervous system involvement. Haematologia
mens and of priming with GM-CSF in older adults with acute myeloid leukemia: A (Budap) 82:577, 1997.
trial by the Eastern Cooperative Oncology Group. Blood 103:479, 2004. 650. Hatano Y, Miura I, Horiuchi T, et al: Cerebellar myeloblastoma formation in CD7-
619. Ganser A, Heil G: Use of hematopoietic growth factors in the treatment of acute mye- positive, neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia
logenous leukemia. Curr Opin Hematol 4:191, 1997. (M1). Ann Hematol 75:125, 1997.
620. Lowenberg B, Van Putten W, Theobald M, et al: Effect of priming with granulocyte 651. Zuckerman T, Ganzel C, Tallman MS, et al: How I treat hematologic emergencies in
colony-stimulating factor on the outcome of chemotherapy for acute myeloid leuke- adults with acute leukemia. Blood 120:1993, 2012.
mia. N Engl J Med 348:743, 2003. 652. Vavricka SR, Walter RB, Irani S, et al: Safety of lumbar puncture for adults with acute
621. Thomas X, Raffoux E, Botton S, et al: Effect of priming with granulocyte-macrophage leukemia and restrictive prophylactic platelet trans-fusion. Ann Hematol 82:570, 2003.
colony-stimulating factor in younger adults with newly diagnosed acute myeloid leu- 653. Slomowitz SJ, Shami PJ: Management of extramedullary leukemia as a presentation of
kemia: A trial by the Acute Leukemia French Association (ALFA) Group. Leukemia acute myeloid leukemia. J Natl Compr Canc Netw 10:1165, 2012.
21:453, 2007. 654. Breccia M, Mandelli F, Petti MC, et al: Clinico-pathological characteristics of myeloid
622. Pabst T, Vellenga E, van Putten W, et al: Favorable effect of priming with granulocyte sarcoma at diagnosis and during follow-up: Report of 12 cases from a single institution.
colony-stimulating factor in remission induction of acute myeloid leukemia restricted Leuk Res 28:1165, 2014
to dose escalation of cytarabine. Blood 119:5367, 2012. 655. Zittoun RA, Madelli F, Willemze R, et al: Autologous or allogeneic bone marrow
623. Nimubona S, Grulois I, Bernard M, et al: Complete remission in hypoplastic acute transplantation compared with intensive chemotherapy in acute myelogenous leuke-
myeloid leukemia induced by G-CSF without chemotherapy: Report on three cases. mia. European Organization for Research and Treatment of Cancer (EORTC) and the
Leukemia 16:1872, 2002. Gruppo Italiano Malattie Ematologiche Maligne dell-Adulto (GIMEMA) Leukemia
624. Schlenk RF, Benner A, Hartmann F, et al: Risk-adapted postremission therapy in acute Cooperative Groups. N Engl J Med 332:217, 1995.
myeloid leukemia: Results of the German multicenter AML HD93 treatment trial. 656. Harousseau JL, Cahn JY, Pignon B, et al: Comparison of autologous bone marrow
Leuk Res 17:1521, 2003. transplantation and intensive chemotherapy as postremission therapy in adult acute
625. Anderlini P, Ghaddar HM, Smith TL, et al: Factors predicting complete remission and myeloid leukemia. The Group Ouest Est Leucemies Aigues Myeloblastiques (GOE-
subsequent disease-free survival after a second course of induction therapy in patients LAM). Blood 90:2978, 1997.
with acute myelogenous leukemia resistant to the first. Leukemia 10:964, 1996. 657. Suciu S, Mandelli F, De Witte T, et al: Allogeneic compared with autologous stem cell
626. Estey EH, Shen Yu, Thall PF: Effect of time to complete remission on subsequent sur- transplantation in the treatment of patients younger than 46 years with acute myeloid
vival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 95:72, 2000. leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of
627. Brandwein JM, Gupta V, Schuh AC, et al: Predictors of response to reinduction che- the EORTC/GIMEMAAML-10 trial. Blood 102:1232, 2003.
motherapy for patients with acute myeloid leukemia who do not achieve complete 658. Bassara N, Schulze A, Wedding U, et al: Early related or unrelated haematopoietic cell
remission with frontline induction chemotherapy. Am J Hematol 83:54, 2008. transplantation results in higher overall survival and leukaemia-free survival com-
628. Tsimberidou AM, Estey E: Induction mortality risk in adult acute myeloid leukemia. pared with conventional chemotherapy in high-risk acute myeloid leukaemia patients
Leuk Lymphoma 47:1199, 2006. in first complete remission. Leukemia 23:635, 2009.
629. Greenwood MJ, Seftel MD, Richardson C, et al: Leukocyte count as a predictor of death 659. Stone RM: Acute myeloid leukemia in first remission: To choose transplantation or
during remission induction in acute myeloid leukemia. Leuk Lymphoma 47:1245, not? J Clin Oncol 31:1262, 2013.
2006. 660. Kurosawa S, Yamaguchi T, Miyawski S, et al: A Markov decision analysis of allogeneic
630. Blum W, Porcu P: Therapeutic apheresis in hyperleukocytosis and hyperviscosity syn- hematopoietic cell transplantation versus chemotherapy in patient with acute myeloid
drome. Semin Thromb Hemost 33:350, 2007. leukemia in first remission. Blood 117:2113, 2011.
631. Schmidt JE, Tamburro RF, Sillos EM, et al: Pathophysiology-directed therapy for acute 661. Stelljes M, Krug U, Beelen DW, et al: Allogeneic transplantation versus chemotherapy
hypoxemic respiratory failure in acute myeloid leukemia with hyperleukocytosis. J as postremission therapy for acute myeloid leukemia: A prospective matched pairs
Pediatr Hematol Oncol 25:569, 2003. analysis. J Clin Oncol 32:388, 2013.
632. Hughes WT, Armstrong D, Bodey GP, et al: 1997 Guidelines for the use of antimicro- 662. Messerer D, Engel J, Hasford J, et al: Impact of different post-remission strategies on
bial agents in neutropenic patients with unexplained fever. Infectious Diseases Society quality of life in patients with acute myeloid leukemia. Haematologica 93:826, 2008.
of America. Clin Infect Dis 25:551, 1997. 663. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute
633. Lehrenbecher T, Varig D, Kaiser J, et al: Infectious complications in pediatric acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of
myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML- prospective clinical trials. JAMA 301:2349, 2009.
BFM 93. Leukemia 18:72, 2004. 664. Shpilberg O, Haddad N, Sofer O, et al: Postremission therapy with two different dose reg-
634. Jagarlamidi R, Kumar L, Kochupillai V, et al: Infections in acute leukemia: An analysis imens of cytarabine in adults with acute myelogenous leukemia. Leuk Res 19:893, 1995.
of 240 febrile episodes. Med Oncol 17:111, 2000. 665. Heil G, Mitrou PS, Hoeizer D, et al: High-dose cytosine arabinoside and daunorubicin
635. Uzun O, Anaissie EJ: Antifungal prophylaxis in patients with hematologic malignan- postremission therapy in adults with de novo acute myeloid leukemia. Long-term
cies: A reappraisal. Blood 86:2063, 1995. follow-up of a prospective multicenter trial. Ann Hematol 71:219, 1995.
636. Glasmacher A, Molitor E, Hahn C, et al: Antifungal prophylaxis with itraconazole in 666. Rowe JM: Uncertainties in the standard care of acute myelogenous leukemia. Leuke-
neutropenic patients with acute leukaemia. Leukemia 12:1338, 1998. mia 15:677, 2001.
637. Cornely OA, Maertens J, Winston DJ et al: Posaconazole vs fluconazole or itraco- 667. Cahn JY, Labopin M, Sierra J, et al: No impact of high-dose cytarabine on the outcome
nazole prophylaxis in patients with neutropenia. N Engl J Med 356:348, 2007. of patients transplanted for acute myeloblastic leukemia in first remission. Acute Leu-
638. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J: Acyclovir prophy- kemia Working Party of the European Group for Blood and Marrow Transplantation
laxis and fever during remission-induction therapy of patients with acute myeloid (EBMT). Br J Haematol 110:308, 2000.
leukemia: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 15:2269, 668. Neubauer A, Maharry K, Mrózek K, et al: Patients with acute myeloid leukemia and
1997. RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and
639. Marr KA: New approaches to invasive fungal infections. Curr Opin Hematol 10:445, Leukemia Group B study. J Clin Oncol 26:4603, 2008.
2003. 669. Byrd JC, Dodge RK, Carroll A, et al: Patients with t(8;21) (q22) and acute myeloid
640. Walter RB, Taylor LR, Gardner KM, et al: Outpatient management following intensive leukemia have superior failure-free and overall survival when repetitive cycles of
induction or salvage chemotherapy for acute myeloid leukemia. Clin Adv Hematol high-dose cytarabine are administered. J Clin Oncol 17:3767, 1999.
Oncol 9: 571, 2013. 670. Tsimberidou AM, Estey E, Cortes JE, et al: Mylotarg, fludarabine, cytarabine (ara-C),
641. Ravandi F: Role of cytokines in the treatment of acute leukemias: A review. Leukemia and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous
20:563, 2006. leukemia. Cancer Chemother Pharmacol 52:449, 2003.
642. Rowe J, Anderson JW, Mazza JJ, et al: A randomized placebo-controlled phase III 671. Schiller G: Dose-intensive treatment of acute myelogenous leukemia: Improved sur-
study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to vival [letter, comment]. J Clin Oncol 13:1828, 1995.
70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative 672. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults
Oncology Group (E1490). Blood 86:457, 1995. with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896, 1994.
643. Hoelzer D, Seipelt G: Granulocyte colony-stimulating factor and granulocyte- 673. Schaich M, Parmentier S, Kramer M, et al: High-dose cytarabine consolidation with
macrophage colony-stimulating factor in the treatment of myeloid leukemia. Curr or without additional amsacrine and mitoxantrone in acute myeloid leukemia: Results
Opin Hematol 2:196, 1995. of the prospective randomized AML2003 trial. J Clin Oncol 31:2094, 2013.
644. Beutler E: Platelet transfusions: The 20,000/microL trigger. Blood 81:1441, 1993. 674. Thomas X, Elhamri M, Ralfoux E, et al: Comparison of high-dose cytarabine and
645. Stanworth SJ, Estcourt LJ, Powder G, et al: A no-prophylaxis platelet-transfusion strat- timed-sequential chemotherapy as consolidation for younger adults with AML in first
egy for hematologic cancers. N Engl J Med 368:1771, 2013. remission: The ALFA-9802 study. Blood 118:1754, 2011.
646. Webert K, Cook RJ, Sigouin CS, et al: The risk of bleeding in thrombocytopenic 675. Elonen E, Almqvist A, Hanninen A, et al: Comparison between four and eight cycles
patients with acute myeloid leukemia. Haematologica 91:1530, 2006. of intensive chemotherapy in adult acute myeloid leukemia: A randomized trial of the
647. Schiffer CA: Granulocyte transfusion therapy. Curr Opin Hematol 6:3, 1999. Finnish Leukemia Group. Leukemia 12:1041, 1998.

Kaushansky_chapter 88_p1373-1436.indd 1425 9/21/15 11:02 AM